What Happened
The Texas Attorney General has launched an investigation into energy drinks, citing concerns over their impact on public health. Meanwhile, the FDA is facing calls to pause its National Priority Voucher drug review program, which was introduced by former commissioner Marty Markary.
New Partnerships and Deals
Bristol Myers Squibb has partnered with China's Hengrui Pharma to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion. This partnership aims to bring new treatments to market and expand the companies' presence in the global pharmaceutical industry.
Why It Matters
The investigation into energy drinks highlights the ongoing concerns over the health impacts of these products, particularly among young people. The FDA's drug review program has also been under scrutiny, with some arguing that it prioritizes speed over safety.
The Impact of Alcohol on Public Health
Alcohol screening and counseling are often overlooked in doctor's visits, despite the significant toll that alcohol can take on public health. This gap in care is costing patients and the healthcare system, and highlights the need for better education and resources.
What Experts Say
"The FDA's National Priority Voucher program is a well-intentioned effort to accelerate the development of new treatments, but it needs to be carefully managed to ensure that safety is not compromised." — Dr. Janet Woodcock, Director of the FDA's Center for Drug Evaluation and Research
Key Numbers
- ****$15.2 billion:** The value of the partnership between Bristol Myers Squibb and Hengrui Pharma
- **12: The number of early-stage drugs being developed through the partnership
Background
The Supreme Court's temporary extension of access to a widely used abortion pill has significant implications for women's health and reproductive rights. The ruling allows the pill to remain available while the court considers whether to allow restrictions on its use.
What Comes Next
The investigation into energy drinks and the FDA's drug review program will be closely watched in the coming weeks and months. The partnership between Bristol Myers Squibb and Hengrui Pharma is expected to lead to new treatments and expanded access to healthcare in the years to come.
Key Facts
- Who: Bristol Myers Squibb and Hengrui Pharma
- When: Announced recently
- Impact: Expanded access to healthcare and new treatments
What Happened
The Texas Attorney General has launched an investigation into energy drinks, citing concerns over their impact on public health. Meanwhile, the FDA is facing calls to pause its National Priority Voucher drug review program, which was introduced by former commissioner Marty Markary.
New Partnerships and Deals
Bristol Myers Squibb has partnered with China's Hengrui Pharma to advance more than a dozen early-stage drugs, in a deal worth up to $15.2 billion. This partnership aims to bring new treatments to market and expand the companies' presence in the global pharmaceutical industry.
Why It Matters
The investigation into energy drinks highlights the ongoing concerns over the health impacts of these products, particularly among young people. The FDA's drug review program has also been under scrutiny, with some arguing that it prioritizes speed over safety.
The Impact of Alcohol on Public Health
Alcohol screening and counseling are often overlooked in doctor's visits, despite the significant toll that alcohol can take on public health. This gap in care is costing patients and the healthcare system, and highlights the need for better education and resources.
What Experts Say
"The FDA's National Priority Voucher program is a well-intentioned effort to accelerate the development of new treatments, but it needs to be carefully managed to ensure that safety is not compromised." — Dr. Janet Woodcock, Director of the FDA's Center for Drug Evaluation and Research
Key Numbers
- ****$15.2 billion:** The value of the partnership between Bristol Myers Squibb and Hengrui Pharma
- **12: The number of early-stage drugs being developed through the partnership
Background
The Supreme Court's temporary extension of access to a widely used abortion pill has significant implications for women's health and reproductive rights. The ruling allows the pill to remain available while the court considers whether to allow restrictions on its use.
What Comes Next
The investigation into energy drinks and the FDA's drug review program will be closely watched in the coming weeks and months. The partnership between Bristol Myers Squibb and Hengrui Pharma is expected to lead to new treatments and expanded access to healthcare in the years to come.
Key Facts
- Who: Bristol Myers Squibb and Hengrui Pharma
- When: Announced recently
- Impact: Expanded access to healthcare and new treatments